Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- AOI +31.5%, MOBL +18.8%, UIS +18%, DTRM +17.5%, ROX +14.2%, FEYE +13.5%, NVDA+8.7%, MTW +8.7%, CTRL +7.1%, XIN +6.8%, EGAN +6.7%, ELLI +5.9%, MCFT +4.5%, BRS+4.3%, SKX +4.1%, IMPV +2.7%, NUAN +2.7%, GLUU +2.6%, AIG +2.1%, MPWR +2.1%,IMMU +1.9%, CCJ +1.9%, ESNT +1.2%, COLM +1%,
M&A news:
- RAD +0.5% (Rite Aid announces progress in sale of assets to Walgreens Boots Alliance)
Other news:
- PIRS +15.9% (Pieris Pharmaceuticals and Seattle Genetics (SGEN) announce multi-program immuno-oncology collaboration -- Seattle Genetics to pay Pieris a $30 mln upfront fee), CTIC +8% (prices 20 mln shares at $3.00), NWL +6.6% (WSJ report that activist Starboard is gearing up for proxy battle), KORS +2.6% (files to delay Form 10-Q for the period ended December 30, 2017), NVO +1.9% (announces that the European Commission has granted marketing authorisation for Ozempic for the treatment of adults with type 2 diabetes), AMD +1.2% (following NVDA results), .
Analyst comments:
- EMR +2.5% (upgraded to Overweight from Neutral at JP Morgan)
- IRBT +2.4% (upgraded to Neutral from Underweight at JP Morgan)
- AIG +2.1% (upgraded to Buy from Neutral at BofA/Merrill)
- AQXP +1.9% (initiated with a Buy at Guggenheim)